Drugs in the Pipeline Baricitinib Alone Authorized for COVID-19 Under Revised EUA Publish Date July 29, 2021 The update was based on data from the COV-BARRIER study.
Drugs in the Pipeline Early Data Show Potential Benefit of Acalabrutinib in Severe COVID-19 Publish Date June 9, 2020 Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.